Company / Operating Cash Flow per Share
Inhibrx Biosciences, Inc. Operating Cash Flow per Share History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$8.97
FY2025
5-year range
-$16.41 / -$4.08
FY2023-FY2025
Trend
-119.7%
vs FY2024
Sector context
#206 of 212
Health Care
What the data says
Among 212 Health Care companies, Inhibrx Biosciences, Inc. is in the bottom 3% for operating cash flow per share. Improved from $-16.41 to $-8.97 over the past 2 years.
Based on SEC 10-K filings.
-8.97 in FY2025.
Improved from $-16.41 to $-8.97 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 212This company -$8.97 Sector average -$14.72
▼
+39.1% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 119.7% year-over-year.
- Ranks #206 out of 212 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$8.97 | -119.7% |
| FY2024 | -$4.08 | +75.1% |
| FY2023 | -$16.41 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026